Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voyager Therapeutics

3.74
+0.10002.75%
Post-market: 3.740.00000.00%19:41 EDT
Volume:235.39K
Turnover:872.57K
Market Cap:206.47M
PE:-3.31
High:3.79
Open:3.58
Low:3.58
Close:3.64
Loading ...

Company Profile

Company Name:
Voyager Therapeutics
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
172
Office Location:
75 Hayden Avenue,Lexington,Massachusetts,United States
Zip Code:
02421
Fax:
- -
Introduction:
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Directors

Name
Position
Steven M. Paul
Director, President and Chief Executive Officer
Glenn F. Pierce
Director
James Arthur Geraghty
Director
Mark Levin
Director
Michael Higgins
Director
Perry Karsen
Director
Steven Hyman
Director
Wendy Dixon
Director

Shareholders

Name
Position
Steven M. Paul
Director, President and Chief Executive Officer
Matthew P. Ottmer
Chief Operating Officer
Jane P. Henderson
Chief Financial Officer and Senior Vice President of Corporate Development
Bernard Ravina
Chief Medical Officer
Dinah Sah
Chief Scientific Officer